Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome

Objectives: Cardiovascular diseases (CVD) remain the leading cause of morbimortality in patients with chronic kidney disease (CKD). The aim of this study was to assess the cardiovascular impact of the pharmacological inhibition of soluble epoxide hydrolase (sEH), which metabolizes the endothelium-de...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamzaoui, Mouad, Roche, Clothilde, Coquerel, David, Duflot, Thomas, Brunel, Valery, Mulder, Paul, Richard, Vincent, Bellien, Jérémy, Guerrot, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991096/
https://www.ncbi.nlm.nih.gov/pubmed/33777999
http://dx.doi.org/10.3389/fmolb.2020.604042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991096/
https://www.ncbi.nlm.nih.gov/pubmed/33777999
http://dx.doi.org/10.3389/fmolb.2020.604042

Ejemplares similares